Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Astrazeneca (AZNCF) EBT (2016 - 2025)

Historic EBT for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to $2.6 billion.

  • Astrazeneca's EBT rose 5780.31% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $12.4 billion, marking a year-over-year increase of 4269.93%. This contributed to the annual value of $12.4 billion for FY2025, which is 4269.93% up from last year.
  • Latest data reveals that Astrazeneca reported EBT of $2.6 billion as of Q4 2025, which was up 5780.31% from $3.2 billion recorded in Q3 2025.
  • Over the past 5 years, Astrazeneca's EBT peaked at $3.4 billion during Q1 2025, and registered a low of -$2.0 billion during Q3 2021.
  • Its 5-year average for EBT is $1.5 billion, with a median of $1.7 billion in 2023.
  • Per our database at Business Quant, Astrazeneca's EBT plummeted by 33458.38% in 2021 and then soared by 74534.41% in 2023.
  • Over the past 5 years, Astrazeneca's EBT (Quarter) stood at -$636.0 million in 2021, then skyrocketed by 222.33% to $778.0 million in 2022, then increased by 15.3% to $897.0 million in 2023, then surged by 85.73% to $1.7 billion in 2024, then skyrocketed by 57.8% to $2.6 billion in 2025.
  • Its EBT stands at $2.6 billion for Q4 2025, versus $3.2 billion for Q3 2025 and $3.1 billion for Q2 2025.